ExpreS2ion will attend and present its ExpreS2 technology platform at several key events in March and April

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate at several key events in March and April, including ISBiotech, March 4-6, in Norfolk, VA, USA, Sedermeradagen, March 12, In Copenhagen, Denmark, and World Vaccine Congress, April 15-17, in Washington, DC, USA. 

During these and additional scientific and business partnering meetings, ExpreS2ion will present the advantages of the ExpreS2 platform for vaccine discovery, development and GMP production. Recent publications have documented progress in projects using the platform, including the RH5.1 blood-stage malaria vaccine development obtaining positive clinical Phase I/IIa trial results (link to October 31, 2018 press release) and the VAR2CSA placenta-borne malaria vaccine development obtaining positive clinical Phase I trial results (link to January 10, 2019 press release).

These events provide excellent opportunities for us to present the company and our ExpreS2 platform projects to customers or potential partners. We invite everyone with an interest in our Company, our platform, or our projects to contact me and my fellow colleagues, so we can meet and discuss any questions, requests or upcoming opportunities within vaccine development and diagnostics,” says ExpreS2ion’s CEO Dr. Steen Klysner.

ExpreS2ion will participate in the following activities in March and April, 2019:

ISBiotech 9th Spring Meeting, March 4-6, Norfolk, VA, USA

Attend the company presentation by our CSO, Dr. Wian de Jongh, on Development of Drosophila S2-Based Vaccine Production Processes. More information at ISBiotech’s website.

Sedermeradagen, March 12, Copenhagen, Denmark

See the company presentation by our CEO, Dr. Steen Klysner, at this investor event either online or attend the meeting by reserving a seat at Sedermeradagen’s website

BIO-Europe Spring, March 25-27, Vienna, Austria
To pre-arrange business meetings with ExpreS2ion representatives, please contact us via email on info@expreS2ionbio.com. More information at BIO-Europe’s website.

BioProcess International Europe (BPI), April 2-5, Vienna, Austria

To pre-arrange technical and business meetings with ExpreS2ion representatives, please contact us via email on info@expreS2ionbio.com. More information at BPI Europe’ website.

13th World Immune Regulation Meeting (WIRM), April 6-9, Davos, Switzerland

To pre-arrange technical and business meetings with ExpreS2ion representatives, please contact us via email on info@expreS2ionbio.com. More information at WIRM’s website.

World Vaccine Congress (WVC), April 14-17, Washington, DC, USA
To learn more about ExpreS2 and our proven, effective solutions for recombinant protein development and production, please contact us via email on info@expreS2ionbio.com. More information at WVC’s website.

Certified Adviser 

Sedermera Fondkommission

E-mail: CA@sedermera.se

Telephone: +46 40-615 14 10

For further information about ExpreS2ion, please contact:

Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS which was founded in 2017.

Tags:

About Us

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS, which was founded in 2017.

Subscribe